3 Biotech Stocks Poised for Growth in 2026

Three small biotech stocks, Axsome Therapeutics, NovoCure, and MBX Biosciences, are poised for growth in 2026. Axsome, with three approved drugs, recently launched Auvelity for Alzheimers agitation, boosting sales by 74%. NovoCures Tumor Treating Fields tech got FDA nod for advanced pancreatic cancer, with brain cancer sales driving revenue. MBX Biosciences, with no revenue yet, is eyeing the weight-loss boom with a monthly obesity drug in late trials. These biotechs offer high risk and breakthrough potential, with low valuations that could surge on patient wins and investor gains. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/78396c71eb1d585d